The patient, who was taking Tecfidera, died earlier this month.» Read More
Pfizer's pursuit of AstraZeneca raises a huge public policy red flag, writes Andrew Ross Sorkin in the New York Times.
Pfizer kicked off the most important week to date in its struggle to gain control of U.K. rival AstraZeneca.
Allergan is set to reject a $46bn offer by rival Valeant Pharmaceutical, a move likely to spur a takeover battle in the US drug-making industry. FT.
It's been a gloomy week for biotech earnings, and many have blamed their poor results on, of all things, the weather.
May the best drug win. That's how Merck Chief Executive Ken Frazier views the rising competition for hepatitis C treatments.
AstraZeneca, the pharmaceutical company fighting off repeated approaches from larger rival Pfizer, has boosted its defense against the raid.
The FDA said that people should use daily aspirin therapy only after assessing the benefits and risks.
Britain's opposition Labour party has called for an inquiry into a potential takeover of British firm AstraZeneca by U.S. drugmaker Pfizer.
Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
The WHO’s recent warning about germs resistant to antibiotics has raised questions about what pharma companies are doing to fight this.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Ian Read, CEO of Pfizer, flew into London for a round of meetings with politicians and investors ahead of an expected fresh bid for AstraZeneca.
GlaxoSmithKline's sales fell 10%, highlighting the pressures behind last week's decision to trade more than $20 billion of assets with Novartis.
Merck reported better-than-expected quarterly earnings, helped by cost cuts and asset sales, but revenue came in slightly below expectations.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Pfizer's $100 billion offer to acquire British rival AstraZeneca is an effort to achieve an "efficient" tax structure, the company said.
Allergan may be more effective in its defense against a hostile takeover bid by Valeant Pharmaceuticals if it makes a purchase of its own, an analyst says.
U.S. drugmaker Eli Lilly reported lower-than-expected quarterly revenue as it was hurt by disappointing sales of its cancer and diabetes drugs.
The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."
Get the best of CNBC in your inbox